HURA Stock Forecast & Price Target

TuHURA Biosciences is viewed favorably because its IFx-2.0 program has shown encouraging early activity, with all three evaluable Phase 1b/2a patients achieving durable partial responses and remaining ongoing at the six-month assessment, which may partially de-risk the Phase 3 study in advanced or metastatic MCC. The opportunity is also broader than the current trial because about 30% of MCC patients have deep-seated tumors, and management expects data from approximately nine patients at ASCO 2027, with possible expansion and FDA discussion if the response rate persists. Beyond IFx-2.0, the company’s 2Q26 update highlighted progress across TBS-2025 and ADC programs, including FDA written responses after IND submission and a planned Phase 1b/2 study in relapsed/refractory NPM1-mutated AML, supporting multiple future catalysts.

TuHURA Biosciences is viewed negatively because its financial position appears precarious, with only $1.0M in cash and equivalents against $8.7M of OpEx in 2Q26, while it has already drawn $5.7M of the available $50M Parkview credit facility as of June 2026. That funding profile suggests ongoing dependence on external capital, and the expectation of additional equity financing to advance its drug candidates creates meaningful dilution risk for existing shareholders. Fundamentally, the company also faces elevated binary risk from clinical failure, potential FDA or foreign regulatory delays, and intense competition from better-resourced biotechnology and pharmaceutical peers.